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Background: Carfilzomib is a next-generation proteasome inhibitor with single-agent activity in patients with
relapsed and refractory multiple myeloma (R/R MM). In PX-171-003-A1, a single-arm phase 2 study of carfilzomib
monotherapy in heavily pretreated patients, the overall response rate was 23.7%, 37% of patients
achieved≥minimal response and median overall survival (OS) was 15.6 months. Based on this study, carfilzomib
was recently approved by the US Food and Drug Administration for the treatment of R/R MM. Herein we describe
the trial design and rationale for a phase 3 randomized study, FOCUS (CarFilzOmib for AdvanCed Refractory
MUltiple Myeloma European Study), being conducted to compare OS after treatment with single-agent carfilzomib
to best supportive care (BSC) regimen in R/R MM.
Methods: Patients must have received ≥3 prior regimens, must be responsive to at least 1 line of therapy, and be
refractory to their most recent therapy. Eligible patients are randomized 1:1 to receive either carfilzomib (28-
day cycles at 20 mg/m2 IV on Days 1–2 of Cycle 1, escalating to 27 mg/m2 IV on Days 8, 9, 15, and 16 and
continuing at 27 mg/m2 through Cycle 9 and Days 1, 2, 15, and 16≥ Cycle 10) or an active BSC regimen
(corticosteroid treatment of prednisolone 30 mg, dexamethasone 6 mg, or equivalent every other day with optional
cyclophosphamide 50 mg PO once daily). Patients will continue treatment until disease progression, unacceptable
toxicity, or treatment discontinuation and will then enter long-term follow-up for survival. The primary endpoint is
OS and secondary endpoints include progression-free survival, overall response rate, and safety. Disease
assessments will be determined according to the International Myeloma Working Group Uniform Response Criteria
with minimal response per European Blood and Marrow Transplantation Group criteria.
Conclusions: This phase 3 trial will provide more rigorous data for carfilzomib, as this is the first carfilzomib study
with OS as the primary endpoint and will not be confounded by crossover and will provide more robust secondary
response and safety results that will add to the data set from prior phase 2 studies. FOCUS will facilitate regulatory
approvals around the world and expand treatment options for patients with R/R MM.
Trial registration: EudraCT No. 2009-016840-38; NCT01302392.
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Multiple myeloma (MM) is the second most common
hematologic malignancy worldwide [1]. Approximately
86,000 cases occur annually worldwide, with the fre-
quency very unevenly distributed and the highest inci-
dence in industrialized areas of Australia/New Zealand,
Europe, and North America [2]. In Europe, MM has an
incidence of 6/100,000 people and is responsible for at
least 19,000 deaths a year [1,3,4]. MM is characterized
by accumulation of abnormal plasma cells in bone mar-
row and monoclonal protein in blood and urine and has
a heterogeneous clinical presentation [1,4]. Monoclonal
gammopathy of undetermined significance (MGUS) con-
sistently precedes development of MM [1].
Although there are MM treatments, the disease
remains incurable and survival is limited to 6 to 7 years
after autologous stem cell transplantation (ASCT) for
patients who undergo the procedure and approximately
3 years in patients who do not [1,5,6]. Current treatments
for relapsed and/or refractory disease include combin-
ation regimens using melphalan or alkylating agents, bor-
tezomib, thalidomide, and lenalidomide with or without
corticosteroids [6]. New therapies in various treatment
settings have substantially improved outcomes for
patients with relapsed and/or refractory disease, although
survival after treatment with all available regimens, in-
cluding those containing novel agents, is approximately
9 months following becoming refractory to these drugs
[7]. Best supportive care (BSC) for patients with
advanced refractory disease for which no approved alter-
native treatment is available may include low-dose gluco-
corticoids and/or low-dose alkylating agents, along with
other supportive and palliative care options [8].
Carfilzomib is a next-generation proteasome inhibitor
that is structurally and mechanistically distinct from bor-
tezomib. It selectively and irreversibly inhibits the
chymotrypsin-like activities of both the constitutive pro-
teasome and the immunoproteasome [9,10]. In preclin-
ical studies, carfilzomib displayed potent cytotoxic and
pro-apoptotic activity across a broad panel of tumor-
derived cell lines; was a potent proteasome inhibitor in
early rodent tissue studies; showed potent inhibition of
the proteasome with rapid and irreversible target bind-
ing despite high systemic clearance in rats; and was well
tolerated in rats and monkeys [11-13].
Early phase 1 studies of carfilzomib showed sustained
proteasome inhibition [14,15] and an acceptable safety
profile in addition to establishing activity and efficacy in
patients with MM [15]. Observation of fever, chills, short-
ness of breath, and/or rigors in these studies led to a selec-
tion of 20 mg/m2 as the initial dose, as well as inclusion of
hydration and concomitant dexamethasone (4-mg predose
during the first cycle). Further investigation subsequently
showed higher doses of carfilzomib to be effective,permitting escalated dosing up to 27 mg/m2 beginning
with Cycle 2 [15-18].
Carfilzomib has shown promising activity and toler-
ability in several phase 2 clinical studies [16]. In PX-171-
003-A1, a large single-arm study of carfilzomib mono-
therapy in heavily pretreated patients with MM, the
overall response rate (ORR) was 23.7% and 37% of
patients achieved at least a minimal response (MR) [17].
The duration of response (DOR) was 7.8 months, and
overall survival (OS) was 15.6 months [17]. In a study of
bortezomib-treated and bortezomib-naïve patients with
relapsed and/or refractory MM, PX-171-004, overall re-
sponse rates (ORR) and clinical benefit response (CBR)
of 17.1% and 31.4% were reported for bortezomib trea-
ted patients [19] and 47.6% and 61.9% were reported for
bortezomib-naïve patients [20]. Additionally, carfilzomib
has been investigated in patients with varying degrees of
renal insufficiency (PX-171-005), and an ORR of 21.3%
was observed with no difference in carfilzomib pharma-
cokinetics detected between the cohorts of patients with
normal, mild, and severe renal dysfunction and no indi-
cation that a change in dose or treatment schedule is ne-
cessary for these patients [21]. Tolerability of extended
treatment duration has been shown in long-term follow-
up of PX-171-003-A1 [22].
A cross-trial safety analysis of 768 patients, including
526 patients from the four phase 2 trials 003-A0, 003-
A1, 004, and 005 revealed an acceptable safety profile
for carfilzomib [23,24]. Importantly, carfilzomib was
associated with a low rate of typically mild to moderate,
non–dose-limiting peripheral neuropathy (PN) and can
be administered to patients with either 1) a history of or
2) pre-existing neuropathy without increased risk of PN.
Additionally, treatment-emergent renal events resulting
in carfilzomib discontinuations were uncommon and
there was no association of worsening renal function
due to carfilzomib treatment. Finally, hematologic AEs,
although common with carfilzomib treatment, were in-
frequently dose-limiting.
Based on the results of the phase 2 trial PX-171-003-
A1, carfilzomib was recently approved by the US Food
and Drug Administration for the treatment of relapsed
and refractory MM. Herein we describe the design and
rationale of the phase 3 randomized study, FOCUS
(CarFilzOmib for AdvanCed Refractory MUltiple Mye-
loma European Study, EudraCT No. 2009-016840-38),
which is expected to provide important information to
facilitate regulatory approvals around the world and ex-
pand treatment options to meet the unmet need of
patients with advanced MM disease.
Methods/design
FOCUS is a phase 3, randomized, open-label, multicen-
ter study comparing 2 treatment regimens for patients
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Objectives
The primary objective of the study is to compare OS in
patients with relapsed and refractory MM shown to be
refractory to their most recent therapy and who have
received all standard approved therapies, randomized to
receive carfilzomib or a defined BSC regimen.
Secondary endpoints include PFS, ORR [stringent
complete response (sCR) + complete response (CR) +
very good partial response (VGPR) + partial response
(PR)], CBR (ORR+MR), disease control rate (DCR;
CBR+ stable disease lasting ≥8 weeks), DOR (calculated
separately for overall response, CBR, and disease control
endpoints), and safety.
Patients
Eligible patients must be at least 18 years of age and have
measurable MM (defined by serum M protein ≥0.5 g/dL
or serum quantitative immunoglobulin A ≥750 mg/dL in
patients with IgA secretory MM and/or urine Bence Jones
protein ≥200 mg/ 24 h), an Eastern Cooperative Oncology
Group (ECOG) Performance Status of 0–2, and a life ex-
pectancy of at least 1 month. Patients must have received
3 or more prior therapeutic regimens, including treatment
with bortezomib (defined as ≥4 cycles at full dose if toler-
ated); must have been responsive to at least 1 line of ther-
apy (defined as a ≥25% decrease in M protein or total
protein) and have relapsed disease, defined as progression
while on or after at least 1 treatment regimen; and must
have been refractory to their most recent therapy, defined
as nonresponsive (eg, stable disease only, or progressive
disease while on treatment), or disease progression within
60 days of discontinuation from therapy. Prior treatments
must have included an immunomodulatory agent, an al-
kylating agent, and a corticosteroid. Additionally, patients
must have adequate hepatic function and creatinine clear-
ance of ≥15 mL/min.
Exclusion criteria include: Waldenström’s macroglobuli-
nemia or IgM myeloma, POEMS (polyneuropathy, orga-
nomegaly, endocrinopathy, monoclonal gammopathy, and
skin changes) syndrome or plasma cell leukemia; major
surgery within 21 days prior to randomization; myocardial
infarction in previous 3 months, New York Heart Associ-
ation Class III/IV congestive heart failure; known human
immunodeficiency virus seropositivity or active hepatitis;
significant neuropathy (Grade ≥3 or Grade 2 with pain) at
randomization; other malignancy in past 3 years; and prior
carfilzomib treatment.
Study design and treatment
The study will be conducted in accordance with the Dec-
laration of Helsinki, the International Conference onHarmonization E6, and any applicable regulatory require-
ments. The protocol and amendments have been reviewed
by an Independent Ethics Committee. Approval has been
provided by the Ethics Committee for each institution or
city where the clinical trial is being held. Written informed
consent will be obtained before any protocol-specific tests
or procedures are conducted. Estimated sample size is 302
patients, and randomization will be stratified based on
number of previous therapies and geographic location
(Europe vs non-Europe). Eligible patients will be rando-
mized in a 1:1 ratio to carfilzomib or BSC regimen
(Table 1). BSC will initiate on Cycle 1 Day 1 and will in-
clude corticosteroid treatment (prednisolone 30 mg every
other day, dexamethasone 6 mg every other day, or
equivalent), with optional cyclophosphamide 50 mg PO
once daily.
Carfilzomib treatment will be given in 28-day cycles at
20 mg/m2 IV on Days 1 and 2 of Cycle 1, escalating to
27 mg/m2 IV for Days 8, 9, 15, and 16 of Cycle 1 and
continuing at 27 mg/m2 for Cycles 2 through 9. For
Cycles 10 and higher, carfilzomib will be given at 27 mg/m2
IV on Days 1, 2, 15, and 16. Oral hydration, IV hydration,
and dexamethasone 4 mg PO or IV during Cycle 1 will be
included in the treatment regimen. Dosing will be modified
as necessary (20 mg/m2, 15 mg/m2, or 11 mg/m2) to man-
age toxicity.
For all patients randomized to carfilzomib, required
concomitant medications during Cycle 1 include dexa-
methasone (4 mg PO or IV) and ciprofloxacin (500 mg
PO QD). Valacyclovir or an equivalent antiviral is also
required for patients treated with carfilzomib who have
a history of herpes zoster. Additional medications that
are permitted include bisphosphonates and other sup-
portive care therapies at the investigator’s discretion.
Uric acid-lowering agents, red blood cell and platelet
transfusions, erythropoiesis-stimulating agents, and
approved growth factors may be given when clinically
indicated. Concurrent treatment with any anticancer
therapy or radiation to large marrow reserves with
therapeutic or palliative intent are not permitted, nor are
corticosteroids at doses higher than those stated in the
protocol. Plasmapheresis is not permitted.
Patients will continue randomized study treatment
until confirmed disease progression (progressive disease,
PD) or unacceptable toxicity. Following confirmation of
PD or discontinuation from study treatment, all patients
will enter long-term follow-up (LTFU) for survival.
Crossover is not allowed upon progression.
Assessment of efficacy
Patients will be evaluated for disease response and pro-
gression according to the International Myeloma Work-
ing Group (IMWG) response criteria [25] and for MR
according to the European Group for Blood and Marrow
Table 1 Study schema
Eligibility criteria Randomization Treatment arms Follow-up
- Measurable multiple myeloma Randomized 1:1 Carfilzomib - Confirmed disease progression
- ECOG performance status 0-2 Stratified based on: Cycle 1: - Long-term follow-up assessments
every 8 weeks until death or study closure
- ≥3 prior therapeutic regimens - 3 vs 4 vs ≥ 5 therapies 20 mg/m2 IV D 1,2
- Responsive to ≥1 line of therapy - Europe vs non-Europe 27 mg/m2 IV D 8, 9, 15, 16
- Relapsed while on or after 1 therapy Cycle 2-9:
- Refractory to most recent regimen 27 mg/m2 IV D 1, 2, 8, 9, 15, 16
Cycle ≥10:
27 mg/m2 IV D 1, 2, 15, 16
Best Supportive Care Regimen
Prednisolone 30 mg QOD
OR
Dexamethasone 6 mg PO QOD
plus optional
Cyclophosphamide 50 mg PO QD
(max 1400 mg/cycle)
D, day; ECOG, Eastern cooperative oncology group; IV, intravenous; PO, oral; QD, every day; QOD every other day.
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occur on Day 1 of each cycle, at the post-treatment visit,
and during LTFU for those who did not have PD prior
to discontinuing treatment. PD must be confirmed by 1)
2 consecutive measurements of rising serum or urine
M-protein, 2) development of new lesions or definite in-
crease in size of existing bone lesions or soft tissue plas-
macytomas, or 3) hypercalcemia attributed solely to
MM. Tumor response for all categories must be con-
firmed by 1) 2 consecutive M-protein measurements, 2)
plasmacytoma evaluation where relevant, 3) no evidence
of new or progressive bone lesions and 4) bone marrow
biopsy for CR/sCR.
Assessment of safety
All patients who receive at least 1 dose of any study-
specific treatment will be included in the safety analysis.
Adverse event (AE) data will be collected at each visit
from the time the patient signs the consent form and
will be coded using the Medical Dictionary for Regula-
tory Activities (MedDRA) and assigned a severity grade
using the National Cancer Institute-Common Termin-
ology Criteria for Adverse Events (NCI-CTCAE) v4.0
grading scale. The investigator may discontinue study
treatments for the following reasons: patient withdrawal
of consent, confirmed PD, unacceptable toxicity, non-
compliance with study procedures, requirement for al-
ternative therapy, and intercurrent illness or worsening
of a chronic condition; however, patients will be encour-
aged to remain on study for survival assessment.
Patients with a dose reduction due to toxicity willremain on study; if the reduced dose is well tolerated,
the patient may be rechallenged with the original dose at
the start of the next cycle.
Statistical analysis
The primary endpoint of the study is OS, defined as the
time from randomization to death due to any cause. The
study will provide 80% power to detect a 30% reduction
in the risk of death. The primary inferential comparison
for OS between treatment groups will use the log-rank
test assessed against an overall 1-sided significance level
of 0.025 stratified by the randomization stratification fac-
tors (number of prior therapies and geographical loca-
tion). The hazard ratio for treatment group will be
estimated using a stratified Cox proportional hazards
model. The distribution of OS times will be summarized
using the Kaplan-Meier method.
An independent data monitoring committee (DMC)
has been convened for this study and will act in an ad-
visory capacity in safeguarding the interests of study
patients, assessing interim safety and efficacy and for
monitoring the overall conduct of the trial.
The inferential tests associated with secondary end-
points PFS, ORR, CBR, DCR, and DOR (including dur-
ation of clinical benefit and duration of disease control)
will be performed in accordance with a closed testing
procedure (CTP) to adjust for the multiplicity. Under
the CTP, if the null hypothesis for the primary endpoint
(OS) is rejected at the 1-sided significance level of 0.025,
then testing of the secondary endpoints will proceed in a
sequential step-down manner and a 1-sided significance
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of secondary endpoints will continue provided the null
hypothesis for each of the previously tested secondary
endpoints is rejected.
The distribution of PFS times will be summarized descrip-
tively using the Kaplan-Meier method. The inferential com-
parison between treatment groups will use the log-rank test
stratified by the randomization stratification factor. The haz-
ard ratio for treatment group will be estimated using a
stratified Cox proportional hazards model. The inferential
comparison between treatment groups for the ORR,
CBR, and DCR endpoints will be made using the
Cochran-Mantel-Haenszel chi-square test, stratified by
the randomization stratification factor. The odds ratio to
measure the relative treatment effect and the 95% CI will
be estimated using the Mantel-Haenszel method. The
DOR will be calculated for patients who achieve sCR,
CR, VGPR, and PR. The inferential comparison between
treatment groups will use the log-rank test stratified by
the randomization stratification factors (region: Europe
vs non-Europe, and number of prior lines of therapy: 3 vs
4 vs ≥5). The duration of overall response will be sum-
marized descriptively using the Kaplan-Meier method.
The comparisons for the primary and secondary effi-
cacy endpoints will be between the 2 randomized treat-
ments groups (Regimen C vs Regimen BSC) based on
the intent-to-treat population (ITT), consisting of all
randomized patients.
Status
FOCUS began enrolling patients in September 2010 with
a target enrolment of 302 patients. Approximately 100
institutions are being recruited to participate. The study
is currently accruing patients in 7 countries and over 40
sites throughout Europe and is expanding to other parts
of the world, with 211 patients enrolled as of the end of
June 2012.
Discussion
Based on results of previous trials with similar carfilzomib
treatment, carfilzomib is anticipated to provide prolonged
disease control compared with BSC [16-18,28]. This phase 3
trial will provide more rigorous data compared with those
already available for carfilzomib, as it will not be confounded
by crossover and is the first carfilzomib study with OS as
the primary endpoint. Additionally, the larger study group
will provide more robust secondary response data, including
PFS and ORR. It has been demonstrated that maximal
response is associated with better outcome in a variety of
different treatment settings [6]. In light of this current view
of the importance of attaining CR in MM, more robust data
will be beneficial.
Previous studies have reported good tolerability for car-
filzomib [22-24]. Carfilzomib has shown specific long-term tolerability in follow-up of the pivotal 171-003-A1
trial, as well as an extension trial in which patients who
completed other carfilzomib studies are eligible to enroll
(PX-171-010, NCT00884312) [17,29]. Additionally, an on-
going phase 1/2 study has shown carfilzomib to be toler-
able at doses up to 56 mg/m2 [18]. The present study will
expand upon the existing carfilzomib single-agent toler-
ability data set.
This is a study of heavily pretreated patients and, simi-
lar to studies with other newer drugs in relapsed and re-
fractory MM, challenges may arise in the interpretation
of the results. A recent study by the IMWG confirmed
that patients generally have a poor outcome after be-
coming refractory to currently available therapies [7].
The IMWG data establish a relevant context for inter-
preting the results of studies involving novel drugs and
provide information regarding the natural history of
relapsed MM. This information will be useful in inter-
preting the results of the present study.
With respect to the study design, the European Medi-
cines Agency (EMEA) strongly recommended evaluating
whether carfilzomib increased survival in heavily-
pretreated patients with MM, necessitating the inclusion
of a BSC comparator arm. This ultimately proved to be
both scientifically and ethically challenging. In particular,
the identification of a universally acceptable salvage regi-
men for treatment of patients with advanced MM is
quite difficult as treatment options for patients with
relapsed and refractory MM are frequently limited due
to concurrent disease or patients’ inability to tolerate
conventional therapies. Several meetings with European
experts in MM were held with the expressed aim of de-
fining an acceptable control arm for this trial. While a
number of individuals suggested testing carfilzomib
against an active control arm, the majority of experts
favored a control arm permitting the use of optional
cyclophosphamide as it has been shown that continuous
low-dose oral cyclophosphamide in combination with
prednisone has resulted in response rates of 41–69%
with OS up to 28.6 months [30-32]. Following careful
thought and consideration of the consensus view, the
lead investigators concluded that the best approach to
address the needs of both patients and the recommenda-
tion of the regulatory agency was for the control arm to
include a standard regimen of dexamethasone (or
equivalent dosing of a comparable glucocorticoid) with
the option of adding continuous low-dose oral
cyclophosphamide.
To address the potential ethical concerns raised by the
trial design, an extension study is planned that will offer
treatment with carfilzomib to control-arm patients who
complete the study, provided that an interim analysis of
the study data demonstrates a statistically significant sur-
vival benefit for carfilzomib relative to BSC. This option
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over to the carfilzomib treatment arm. Furthermore,
patients are not restricted from receiving further anti-
myeloma therapy following study drug discontinuation.
In conclusion, the results of FOCUS in patients with
relapsed and refractory MM will provide important in-
formation to facilitate regulatory approvals around the
world and expand treatment options to meet the unmet
need of these patients with advanced disease.
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